VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
AstraZeneca (South Korea) · AstraZeneca (France) · +6 more institutions
Abstract
Accurate variant calling in next generation sequencing (NGS) is critical to understand cancer genomes better. Here we present VarDict, a novel and versatile variant caller for both DNA- and RNA-sequencing data. VarDict simultaneously calls SNV, MNV, InDels, complex and structural variants, expanding the detected genetic driver landscape of tumors. It performs local realignments on the fly for more accurate allele frequency estimation. VarDict performance scales linearly to sequencing depth, enabling ultra-deep sequencing used to explore tumor evolution or detect tumor DNA circulating in blood. In addition, VarDict performs amplicon aware variant calling for polymerase chain reaction (PCR)-based targeted…
Citation impact
- FWCI
- 25.77
- Percentile
- 100%
- References
- 34
Authors
10- ZLZhongwu LaiCorresponding
AstraZeneca (South Korea), AstraZeneca (France), AstraZeneca (Brazil), AstraZeneca (United States)
- AMAleksandra Markovets
AstraZeneca (United States)
- MAMiika Ahdesmäki
AstraZeneca (United Kingdom)
- BCBrad Chapman
Harvard University
- OHOliver Hofmann
Harvard University, Cancer Research UK, University of Glasgow
Topics & keywords
- Biology
- DNA sequencing
- Indel
- Amplicon
- Cancer genome sequencing
- Deep sequencing
- Computational biology
- Minion
- Good health and well-being